Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavir
Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to affordable generics in India, warn civil society organisations.
US-based pharma giant Gilead Sciences wants HIV drug Lenacapavir patented
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's applications, the organisation claimed.
Patent opposition case against Gilead’s long-acting HIV injectable drug, comes up this week
The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case scheduled to come up this week at the Indian Patent Office (IPO). Civil society group Sankalp Rehabilitation Trust had opposed Gilead’s patent application on the grounds that it was a known compound.
Patent applications for HIV prevention drug opposed in India
Indian Patent Office to hear objections against Gilead's Lenacapavir patent claims, crucial for affordable HIV treatment worldwide.
GlobalData on MSN
4d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
8d
on MSN
Gilead’s HIV Shot Reduced Infections By 96% In Late-Stage Trial—Beating Daily Pill
Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...
BioSpace
7d
Gilead Touts 96% HIV Risk Reduction With Twice-Yearly PrEP, Eyes Regulatory Filings
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
AOL
7d
Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says
Drugmaker
Gilead
Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...
newsbytesapp.com
2d
Meet Lenacapavir: The drug that could end HIV epidemic
Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...
4d
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
Yahoo Finance
5d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead
Sciences’ capsid inhibitor
lenacapavir
has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early
lenacapavir
...
gaycitynews
13h
Injectable PrEP continues to show promising results
There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...
5d
Hold Rating on Gilead Sciences Amid Lenacapavir’s Promise and Market Uncertainties
Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback